Trial
NCT03224819
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Early Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Amgen
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
Emerfetamab
Why stopped
Priortization of other Programs
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-01